Search
Tivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalIt was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Netupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy … The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
Dienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalIt is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. … Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties.
Tobramycin
go.drugbank.com/drugs/DB00684ApprovedInvestigational[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. … [A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to
Lacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigationalLacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. … [A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigational[L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
Xanthinol
go.drugbank.com/drugs/DB09092ApprovedWithdrawn[L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy … Xanthinol is a very potent water-soluble derivative of niacin that can be found in diet supplements. It is also known as xanthinol nicotinate.
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalFirst developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017. … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.
Phosphatidyl serine
go.drugbank.com/drugs/DB00144ApprovedNutraceuticalBecause of the potentail cognitive benefits of phosphatidylserine, the substance is sold as a dietary supplement to people who believe they can benefit from an increased intake. … This is part of the process by which the cell is targeted for phagocytosis. PS has been shown to slow cognitive decline in animal models.